Clinical trials: Co-Infection HIV-HCV
HIV Infection, Hepatitis C Infection
Study on Immunopathogenesis in HIV and Hepatitis C Coinfection
Liver-related death is the leading cause of mortality in HIV-infected individuals with CD4+ cell counts over 200, and hepatitis C virus (HCV) infection is the greatest risk for liver-related mortality in HIV-positive patients.
- Conditions
- HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
- Trial name
- NCT01296529
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Rush University Medical Center
Hepatitis C, Liver Cirrhoses
Simplified Monitoring Myanmar SM2 Study
The study will evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12) following a course of DAA therapy delivered using a simplified schedule of safety and virological monitoring.
- Conditions
- Hepatitis C, Liver Cirrhoses, Liver Inflammation, HIV Infections
- Trial name
- SM2 (NCT04113629)
- Testing
- HCV point of care machine
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Kirby Institute
HIV, Hepatitis B
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
The EuroSIDA study is a prospective observational cohort study of 23,000+ patients followed in 100+ clinics in 35 European countries, Israel and Argentina.
- Conditions
- HIV, Hepatitis B, Hepatitis C, AIDS
- Trial name
- EuroSIDA (NCT02699736)
- Where
- 110 sites in Argentina, Austria and 34 more
- Volunteers
- 23,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chronic Hepatitis C
Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection
This clinical study will evaluate whether grazoprevir and elbasvir is efficacious, safe, and well-tolerated in peginterferon alfa plus ribavirin experienced patients who inject drugs (PWID) and men who sex with men (MSM) with…
- Trial name
- NCT03098121
- Testing
- grazoprevir and elbasvir
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Taoyuan General Hospital
Hemophilia, AIDS
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
Background: Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also co-infected with HCV. Thus, hemophiliacs represent an important population for studies of the natural history of these chronic…
- Trial name
- NCT00340548
- Where
- 15 sites in United States
- Volunteers
- 333 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections, Hepatitis C
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than interferon-alfa-2a (IFN) plus ribavirin for patients infected…
- Trial name
- NCT00008463
- Testing
- Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
- Where
- 24 sites in United States
- Volunteers
- 132 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Hepatitis C
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV).
- Trial name
- NCT01423643
- Where
- United States
- Volunteers
- 1,250 people
- Sponsor
- Johns Hopkins University
HCV Coinfection, Liver Disease
deLIVER: Direct Acting Antiviral Effects on the Liver
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting…
- Conditions
- HCV Coinfection, Liver Disease, HIV
- Trial name
- deLIVER (NCT02938013)
- Testing
- Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Liver Cirrhosis
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
- Trial name
- OP-724-H202 (NCT07681089)
- Testing
- Foscenvivint
- Where
- 4 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Kiminori Kimura, MD
Liver Cirrhosis
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.
- Trial name
- NCT06144086
- Testing
- Foscenvivint
- Where
- 3 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Kiminori Kimura, MD